The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Aβ oligomer level and attenuating oxidative stress and neuroinflammation
Abstract
Alzheimer's disease (AD) is a progressive, neurodegenerative disease characterized by extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary tangles in the brain. Aβ aggregation is closely associated with neurotoxicity, oxidative stress, and neuronal inflammation. The soluble Aβ oligomers are believed to be the most neurotoxic form among all forms of Aβ aggregates. We have previously reported a polyphenol compound rutin that could inhibit Aβ aggregation and cytotoxicity, attenuate oxidative stress, and decrease the production of nitric oxide and proinflammatory cytokines in vitro. In the current study, we investigated the effect of rutin on APPswe/PS1dE9 transgenic mice. Results demonstrated that orally administered rutin significantly attenuated memory deficits in AD transgenic mice, decreased oligomeric Aβ level, increased super oxide dismutase (SOD) activity and glutathione (GSH)/glutathione disulfide (GSSG) ratio, reduced GSSG and malondialdehyde (MDA) levels, downregulated microgliosis and astrocytosis, and decreased interleukin (IL)-1β and IL-6 levels in the brain. These results indicated that rutin is a promising agent for AD treatment because of its antioxidant, anti-inflammatory, and reducing Aβ oligomer activities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rutin, a major compound found in A. graveolens, has been identified as a promising agent for the treatment of Alzheimer’s disease due to its antioxidant, antiinflammatory, and β-amyloid oligomer reducing activities37.”
From Synergistic and antagonistic contributions of main components to the bioactivity profile of Anethum graveolens extract (2025) · cites this paper as [37]
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Unfolding the role of protein misfolding in neurodegenerative diseases
Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506
Microglia-specific localisation of a novel calcium binding protein, Iba1
Ito, D., Imai, Y., Ohsawa, K., Nakajima, K., Fukuuchi, Y., & Kohsaka, S. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00040-0 · Cited by 1,476
Structural Classification of Toxic Amyloid Oligomers
Glabe, C. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800016200 · Cited by 783
Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489
Microglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291
Research works printed but not linked: 37
- Smid, 2012, Dietary polyphenol-derived protection against neurotoxic beta-amyloid protein: from molecular to clinical, Food Funct, 3, 1242, 10.1039/c2fo30075c · DOI
- Darvesh, 2010, Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents, Expert Rev Neurother, 10, 729, 10.1586/ern.10.42 · DOI
- Choi, 2012, Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease, Brain Res Bull, 87, 144, 10.1016/j.brainresbull.2011.11.014 · DOI
- Capiralla, 2012, Resveratrol mitigates lipopolysaccharide- and Abeta-mediated microglial inflammation by inhibiting the TLR4/NF-kappaB/STAT signaling cascade, J Neurochem, 120, 461, 10.1111/j.1471-4159.2011.07594.x · DOI · Paper page
- Rubio-Perez, 2012, A review: inflammatory process in Alzheimer's disease, role of cytokines, Scientific World Journal, 7563, 57
- Arjumand, 2011, Rutin attenuates cisplatin induced renal inflammation and apoptosis by reducing NFkappaB TNF-alpha and caspase-3 expression in wistar rats, Food Chem Toxicol, 49, 2013, 10.1016/j.fct.2011.05.012 · DOI
- Gupta, 2003, Neuroprotective effect of antioxidants on ischaemia and reperfusion-induced cerebral injury, Pharmacol Res, 48, 209, 10.1016/S1043-6618(03)00102-6 · DOI
- Pu, 2007, Neuroprotective effects of quercetin and rutin on spatial memory impairment in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats, J Pharmacol Sci, 104, 329, 10.1254/jphs.FP0070247 · DOI
- Javed, 2012, Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type, Neuroscience, 210, 340, 10.1016/j.neuroscience.2012.02.046 · DOI
- Koda, 2009, Rutin supplementation in the diet has protective effects against toxicant-induced hippocampal injury by suppression of microglial activation and pro-inflammatory cytokines: protective effect of rutin against toxicant-induced hippocampal injury, Cell Mol Neurobiol, 29, 523, 10.1007/s10571-008-9344-4 · DOI
- Khan, 2009, Rutin protects the neural damage induced by transient focal ischemia in rats, Brain Res, 1292, 123, 10.1016/j.brainres.2009.07.026 · DOI
- Wang, 2012, Rutin inhibits beta-amyloid aggregation and cytotoxicity, attenuates oxidative stress, and decreases the production of nitric oxide and proinflammatory cytokines, Neurotoxicology, 33, 482, 10.1016/j.neuro.2012.03.003 · DOI
- Vorhees, 2006, Morris water maze: procedures for assessing spatial and related forms of learning and memory, Nat Protoc, 1, 848, 10.1038/nprot.2006.116 · DOI · Paper page
- Hao, 2011, Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology, Brain, 134, 278, 10.1093/brain/awq325 · DOI
- Sun, 2011, Protective effects of bone morphogenetic protein 7 against amyloid-beta induced neurotoxicity in PC12 cells, Neuroscience, 184, 151, 10.1016/j.neuroscience.2011.03.059 · DOI
- Winterbourn, 1999, Protein carbonyl measurement by enzyme-linked immunosorbent assay, Methods Enzymol, 300, 106, 10.1016/S0076-6879(99)00118-4 · DOI
- Khan, 2012, Protective effects of rutin against potassium bromate induced nephrotoxicity in rats, BMC Complement Altern Med, 12, 204, 10.1186/1472-6882-12-204 · DOI
- Freeman, 1982, Biology of disease: free radicals and tissue injury, Lab Invest, 47, 412
- Lovell, 2007, Oxidative damage in mild cognitive impairment and early Alzheimer's disease, J Neurosci Res, 85, 3036, 10.1002/jnr.21346 · DOI
- Glabe, 2004, Conformation-dependent antibodies target diseases of protein misfolding, Trends Biochem Sci, 29, 542, 10.1016/j.tibs.2004.08.009 · DOI
- O’Nuallain, 2002, Conformational Abs recognizing a generic amyloid fibril epitope, Proc Natl Acad Sci USA, 99, 1485, 10.1073/pnas.022662599 · DOI
- Glabe, 2006, Common mechanisms of amyloid oligomer pathogenesis in degenerative disease, Neurobiol Aging, 27, 570, 10.1016/j.neurobiolaging.2005.04.017 · DOI · Paper page
- Kayed, 2004, Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases, J Biol Chem, 279, 46363, 10.1074/jbc.C400260200 · DOI
- Bucciantini, 2004, Prefibrillar amyloid protein aggregates share common features of cytotoxicity, J Biol Chem, 279, 31374, 10.1074/jbc.M400348200 · DOI
- Prangkio, 2012, Multivariate analyses of amyloid-beta oligomer populations indicate a connection between pore formation and cytotoxicity, PLoS ONE, 7, e47261, 10.1371/journal.pone.0047261 · DOI
- Camilleri, 2013, Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols, Biochim Biophys Acta, 1828, 2532, 10.1016/j.bbamem.2013.06.026 · DOI
- Demuro, 2005, Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers, J Biol Chem, 280, 17294, 10.1074/jbc.M500997200 · DOI
- Zhang, 2011, Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses, Biochim Biophys Acta, 1814, 1703, 10.1016/j.bbapap.2011.09.005 · DOI
- Moreira, 2005, Oxidative stress: the old enemy in Alzheimer's disease pathophysiology, Curr Alzheimer Res, 2, 403, 10.2174/156720505774330537 · DOI
- Butterfield, 2001, Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide, Trends Mol Med, 7, 548, 10.1016/S1471-4914(01)02173-6 · DOI · Paper page
- Dringen, 2000, Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species, Eur J Biochem, 267, 4912, 10.1046/j.1432-1327.2000.01597.x · DOI
- Stanley Mainzen Prince, 2006, Rutin improves glucose homeostasis in streptozotocin diabetic tissues by altering glycolytic and gluconeogenic enzymes, J Biochem Mol Toxicol, 20, 96, 10.1002/jbt.20117 · DOI
- Murakami, 2011, SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease, J Biol Chem, 286, 44557, 10.1074/jbc.M111.279208 · DOI · Paper page
- Verri, 2012, Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease, Int J Immunopathol Pharmacol, 25, 345, 10.1177/039463201202500204 · DOI
- Overmyer, 1999, Astrogliosis and the ApoE genotype. an immunohistochemical study of postmortem human brain tissue, Dement Geriatr Cogn Disord, 10, 252, 10.1159/000017128 · DOI
- Smith, 2010, Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease, Int J Pharm, 389, 207, 10.1016/j.ijpharm.2010.01.012 · DOI · Paper page
- Smith, 2011, Cocrystals of quercetin with improved solubility and oral bioavailability, Mol Pharm, 8, 1867, 10.1021/mp200209j · DOI
Cited by
Anti-inflammatory Effects of Flavonoids in Neurodegenerative Disorders
Spagnuolo, C., Moccia, S., & Russo, G. L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.001 · Cited by 458
Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease
Seo, E.-J., Fischer, N., & Efferth, T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.030 · Cited by 265
Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240
Barbosa, M., Valentão, P., & Andrade, P. (2014) · Marine Drugs · doi:10.3390/md12094934 · Cited by 181
Hu, B., Dai, F., Fan, Z., Ma, G., Tang, Q., & Zhang, X. (2015) · Advanced Materials · doi:10.1002/adma.201502227 · Cited by 155
Metadata
- Authors
- Xu, P.-X., Wang, S.-W., Yu, X.-L., Su, Y.-J., Wang, T., Zhou, W.-W., Zhang, H., Wang, Y.-J., & Liu, R.-T.
- Venue
- Behavioural Brain Research
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 264
- Pages
- 173-180
- ISSN
- 0166-4328
- Cited by
- 232
- References
- 7
- Language
- en
- Funders
- National Natural Science Foundation of China (30971012, 81171014)
- National Science and Technology Major Projects of New Drugs (2012ZX09103301-001, 2014ZX09102041-007)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Aβ oligomer level and attenuating oxidative stress and neuroinflammation. https://app.cochat.ai/papers/10.1016/j.bbr.2014.02.002
- The paper
- Xu, P.-X., Wang, S.-W., Yu, X.-L., Su, Y.-J., Wang, T., Zhou, W.-W., Zhang, H., Wang, Y.-J., & Liu, R.-T. (2014). Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Aβ oligomer level and attenuating oxidative stress and neuroinflammation. Behavioural Brain Research. https://doi.org/10.1016/j.bbr.2014.02.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.